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ABSTRACT 
 
  
Background 
 
Gestational diabetes mellitus (GDM) is a major clinical challenge and is likely to remain so as 
the incidence of GDM continues to increase 
Aim 
 
To assess longitudinal changes in maternal haemodynamics amongst women diagnosed 
with GDM requiring either metformin or dietary intervention in comparison to low-risk 
healthy controls. 
Methodology 
 
Fifty-six pregnant women attending their first appointment at the GDM clinic and 60 low-
risk healthy pregnant controls attending their routine antenatal clinics were recruited and 
assigned to three groups: GDM Metformin (GDM-M), GDM Diet (GDM-D) and Control. Non-
invasive assessment of maternal haemodynamics, using recognised measures of  arterial 
stiffness and central blood pressure (Arteriograph®), were undertaken under controlled 
conditions within four gestational windows: antenatal; AN1 (26-28 weeks), AN2 (32-34 
weeks) and AN3 (37-40 weeks), and postnatal (PN) (6-8 weeks after delivery). Data were 
analysed using a linear mixed model incorporating gestational age and other relevant 
predictors, including age, blood pressure (BP), baseline bodyweight and pulse as fixed 
effects, and patient as a random effect.  
Results 
Fitted linear mixed models showed evidence of a two-way interaction effect between 
groups (GDM-D, GDM-M and Control) and stages of gestation (AN1, AN2, AN3 and PN) for 
maternal haemodynamic parameters: brachial artery augmentation index (AIx) (p=0.004), 
aortic AIx (p=0.008), and central systolic BP (p=0.001).  However, differences in respect of 
aortic pulse wave velocity (p=0.001) and heart rate (p<0.001) were only significant for 
gestational stage. At AN2, we did not observe any evidence that the mean brachial Aix in the 
GDM-M was different from the control group (p=0.158). 
  
Conclusion 
 
AIx and central systolic BP measures of arterial stiffness are adversely affected by GDM in 
comparison to controls during pregnancy. The possible beneficial effects of metformin 
therapy seen at 32 to 34 weeks of gestation require further exploration.  
  
  
INTRODUCTION 
 
Pregnancy is associated with significant changes in maternal haemodynamics and measures 
of arterial stiffness across each trimester(1).  In particular, significant increases in arterial 
stiffness and wave reflection parameters are noted amongst pregnant women who 
subsequently develop pre-eclampsia and small for gestational age foetuses(2), as well as 
those with known pre-eclampsia(3). Cross-sectional studies(4-6) conducted in late 
pregnancy or immediately post-partum have suggested an independent link between 
arterial stiffness and gestational diabetes mellitus (GDM), with increased pulse wave 
velocity (PWV) and augmentation index (AIx) in GDM compared to women with normal 
glucose tolerance. Furthermore, GDM may be associated with chronic effects on vascular 
haemodynamics, impacting longer-term outcomes. Women with a history of GDM have 
evidence of endothelial dysfunction and are at increased risk of vascular complications 
independent of known risk factors(7, 8). However, these studies are limited by sample size 
and are cross-sectional in nature.  A clearer understanding of changes in arterial stiffness 
throughout pregnancy and post-partum between GDM and healthy women may be of 
predictive value. 
Pregnancy-associated diabetes has historically only been treated with dietary modification 
and/or insulin. Metformin was also considered unsafe, as the drug crosses the placenta, 
posing a potential threat to the foetus. Glyburide, a sulphonylurea, was the second line 
treatment after Insulin in the US for GDM. However, it has now superseded insulin as the 
most common treatment since 2007; being used in over 64.5% of women with GDM(9). 
Though this change was due to the perception that Glyburide does not cross the 
placenta(10), there have been reports of an increased rate of pre-eclampsia, neonatal 
jaundice requiring phototherapy, increased duration of stay in the neonatal unit, 
macrosomia and neonatal hypoglycaemia following its use(11). Results from a systematic 
review and meta-analysis established that glyburide is inferior to both metformin and 
insulin in the treatment of women with GDM(12). Results from several observational and 
randomised trials over the past decade have confirmed that metformin use in pregnancy is 
safe, with no evidence of increased birth defects or other pregnancy-related 
complications(13-16), though it remains unlicensed for use in pregnancy.  
  
GDM is now treated with dietary and lifestyle modification, metformin and if needed 
insulin(17). Metformin may have cardiovascular benefits(18); the UK Prospective Diabetes 
Study (UKPDS) demonstrating that metformin use in obese patients with type 2 diabetes is 
associated with beneficial effects on cardiovascular disease outcomes, with a 36% and 39% 
relative risk reduction in all-cause mortality and myocardial infarction, respectively(19). In a 
randomised, placebo controlled trial, short-term metformin therapy was found to improve 
arterial stiffness and endothelial function in young women with polycystic ovarian syndrome 
(PCOS)(20).  
It is important to assess whether metformin use may be associated with potential benefits 
on vascular stiffness in GDM, as this may also be associated long-term cardiovascular 
benefit. Therefore, a pilot study was undertaken to assess i) longitudinal changes in 
maternal haemodynamics, including AIx and PWV parameters among pregnant women with 
GDM compared to healthy pregnancy; and ii) to explore whether metformin compared to 
diet-only modification had beneficial effects on maternal haemodynamic assessments.  
METHODS 
 
Fifty-six consecutive women with a singleton viable pregnancy attending their first 
appointment at the GDM clinic and a further 60 low-risk healthy pregnant women attending 
their routine antenatal dating ultrasound scan at the University Hospitals of Leicester NHS 
Trust, were invited to participate in the study. Screening for women at risk of GDM is always 
offered to pregnant women with: BMI greater than 30kg/m2, previous macrosomic baby 
weighing more than 4.5kg, previous history of GDM, family history of diabetes in a first 
degree relative, or of minority ethnic origin with a high prevalence of diabetes(17). 
Screening was offered at 24-28 weeks of gestation and diagnosis of GDM was made if the 
woman had either: a fasting plasma glucose level of 5.6 mmol/litre or above OR a 2-hour 
plasma glucose level of 7.8 mmol/litre or above(17). 
 Women screening positive for GDM were included into the GDM group. Participants were 
excluded if they were current smokers, had a multiple pregnancy, foetal anomalies, pre-
pregnancy or pregnancy-induced hypertension, pre-eclampsia, thyroid disease requiring 
medication, renal disease, type1 or 2 diabetes mellitus, GDM requiring insulin or were 
  
taking any medication that could affect the cardiovascular system. In addition, eligibility into 
the control group required the participants to have body mass index (BMI) between 18.5-
24.9Kg/m2 at booking and not to have diabetes mellitus. 
Following informed written consent (Stanmore National Research Ethics Committee, 
Reference 12/LO/0810), maternal characteristics, including medical history, were obtained. 
Participants were separated into two groups, GDM and control. The GDM group was further 
divided into two groups according to GDM management: diet modification (GDM-D) or 
metformin therapy (GDM-M). Upon diagnosis of GDM, women were reviewed in a 
multidisciplinary GDM clinic with a diabetes nurse and dietician, and were counselled on the 
diagnosis and dietary changes needed. They were then reviewed two weeks later at around 
30 to 31 weeks of gestation to review the effects of dietary adjustments on blood sugar 
control. Women with poor control were then immediately started on metformin (500mg po 
bd) and therefore all women in the GDM-M group were on metformin during the AN2 and 
AN3 measurements. Compliance was monitored by checking the electronic readings stored 
on the glucometer by the diabetic physician and women requiring insulin were excluded 
(n=4). 
 
Participants were assessed at four gestational windows: antenatal 26-28 [AN1], 32-34 [AN2] 
and 37-40 weeks [AN3]) and post-natal at 6-8 weeks after delivery [PN]. They were assessed 
in a temperature-controlled room (22°C) in a semi recumbent position. Participants were 
rested for a minimum of ten minutes, and were free from distraction, including speaking 
and moving, during the assessments. Assessments were not carried out following a large 
meal or caffeine intake. Arterial stiffness measurements of PWV and AIx were obtained with 
the Arteriograph® (Tensiomed Ltd, Hungary). The Arteriograph® cuff was applied to the right 
arm over the brachial artery for an estimation of central systolic blood pressure (BP), aortic 
PWV and AIx, as previously described(21). Recordings were made by one observer (MWO), 
who had received appropriate training in use of the Arteriograph®.  
Statistical analysis 
 
We modelled the changes at gestational and post-natal stages for brachial and aortic AIx, 
and PWV, by separate linear mixed models, incorporating group (three levels: Diet [GDM-D], 
  
Metformin [GDM-M] and Control), and gestational stage (four levels: AN1, AN2, AN3, PN), 
as fixed effects and individual participant as a random effect. If statistically significant 
(p<0.05), the final model also included the two-way interaction term of group and 
gestational stage. The final models for brachial and aortic Aix also included baseline body 
weight, heart rate and central mean arterial pressure as additional fixed effects, while 
baseline body weight, heart rate and systolic blood pressure were included as fixed effects 
for PWV. The variables height and age did not demonstrate a significant effect either in 
single or multi-variable models; hence were not considered in the final model. Since the 
two-way interaction effect of group and gestational stage for brachial and aortic AIx and 
central systolic BP was statistically significant, we compared the mean differences between 
Control, GDM-D and GDM-M groups at each of the four gestational windows and the 
estimated probabilities of 12 mean differences were subsequently adjusted by Bonferroni 
correction to account for multiple comparisons. For variables where the two-way 
interaction effect was not statistically significant, we did not conduct any treatment group 
comparison at the predefined time points. 
All statistical tests were two-sided with type 1 error rate (p-value) of 0.05 to determine 
statistical significance. All statistical analyses were carried out using the R software version 
3.3 with appropriate R packages (nlme, multcomp, ggplot2) (R Core Team, 2016). 
RESULTS  
 
A total of one hundred and sixteen women were recruited to the study; 56 women with 
GDM, of whom 33 of mean age 31.7 years (SD 5.4 years) were in the GDM-M group and 23 
of mean age 33.1 years (4.7 years) were in the GDM-D group, and 60 women of mean age 
29.7 years (SD 5.3 years) in the control group. Baseline characteristics are described in Table 
1.  
  
  
Brachial Augmentation index 
 
The fitted linear mixed model showed strong evidence of a two-way interaction effect 
between group (Control, GDM-D and GDM-M) and gestational stage (AN1, AN2, AN3 and 
PN) for brachial AIx (p=0.004) and aortic AIx (p=0.008) after adjusting for heart rate, central 
mean arterial pressure and baseline body weight.(Table 2 and Supplementary Tables 1 and 
2, Figure 1). At AN1, the mean (±SE) brachial AIx (%) of GDM-M (-58.20±2.41) was 
significantly different (adjusted p = 0.020) from the control group (-68.15±1.78). The mean 
difference between brachial AIx (%) GDM-D (-59.02±2.65) although showed statistically 
significance (p=0.005) before Bonferonni correction, the adjusted p-value (0.055), however, 
exceeded the pre-assigned type 1 error of 0.05. There was no evidence that mean brachial 
AIx were significantly different between two GDM groups at AN1 (p=0.817). At AN2, only 
the mean difference between GDM-D (-46.53±3.80) and control (-68.91±2.32) groups was 
statistically significant (adjusted p<0.001). We did not observe mean brachial AIx values 
were significantly different between groups at AN3, however, postnatally, both GDM-M (-
24.25±8.23) and GDM-D(-24.21±6.90)  were significantly different from the control (-
44.10±3.76) group (adjusted p=0.023 and 0.034, respectively). There was no evidence that 
mean brachial AIx differed between GDM-M and GDM-D postnatally (p=0.790). 
Aortic augmentation index 
 
Similar to brachial AIx , we also found strong evidence (p=0.008) of a  two-way interaction 
effect between group (Control, GDM-D and GDM-M) and gestational stage (AN1, AN2, AN3 
and PN) for aortic AIx following adjustment for baseline body weight, heart rate and central 
mean arterial pressure (Table 2 and Supplementary Tables 1 and 2 , Figure 2).  At AN1, the 
mean (±SE) aortic AIx (%) of GDM-M (8.08±1.25) was significantly different (adjusted p = 
0.033) from the control group (3.18±0.92). The mean difference between aortic AIx (%) 
GDM-D (6.99±1.38) was statistically significant (p=0.023), but following Bonferroni 
correction, the adjusted p-value (0.277) exceeded the pre-assigned type 1 error of 0.05. On 
the other hand, only the mean difference of aortic AIx between GDM-D (12.72±1.97) and 
control (2.84±1.20) groups was statistically significant (adjusted p<0.001) at AN2. We did 
not observe mean aortic AIx values were significantly different between groups at AN3. 
  
Postnatally, both GDM-M (17.53±2.39) and GDM-D (16.86±2.21) were significantly different 
from the control (8.94±1.75) group (adjusted p=0.036 and 0.030, respectively). There was 
no evidence that mean aortic AIx differed between GDM-M and GDM-D postnatally 
(p=0.828). 
 
Pulse wave velocity 
 
Only mean differences between gestational stages (p=0.003), not between groups 
(p=0.511), were statistically significant for PWV, after adjusting for baseline body weight, 
heart rate and systolic blood pressure (Table 2 and Supplementary Tables 1 and 2, Figure 3). 
The mean PWV values were significantly higher at AN2 (p=0.005) and PN (p=0.003) 
compared with the value at AN1, but the mean PWV at AN3 was not significantly different 
from the mean PWV at AN1 (p=0.458).
  
DISCUSSION 
 
This longitudinal pilot study has demonstrated that pregnancies affected by GDM may be 
associated with significant alterations in maternal haemodynamics, as demonstrated by 
temporal changes in AIx, BP and PWV. Exploring the effect of metformin on maternal 
haemodynamics, we observed a potential interaction effect suggesting that metformin may 
attenuate the GDM associated AIx rise during the second trimester as demonstrated 
between 32-34 weeks of pregnancy. 
Our study describes differences in arterial stiffness measurements over the course of GDM 
and normal glucose tolerant pregnancies.  However, apart from AIx, there was no significant 
difference in arterial stiffness parameters between the GDM and control groups in 
pregnancy or postpartum. Further merit is given to this finding when the comparison is 
performed at PN. The GDM-M group would now not be on any therapy, as metformin is 
stopped on the day of delivery, yet we found a significant mean difference between the 
GDM-D and GDM-M vs the control group, with a marked increase in AIx in the GDM 
metformin group at PN. This trend could mean that metformin may offer a protective effect 
on the vasculature and once stopped, the protection ceases.  This is in keeping with the 
understanding that AIx may reflect the early changes of arterial stiffness, as the changes are 
more prevalent in younger individuals (age<50years), whereas, PWV may reflect the later or 
chronic changes in arterial stiffness as age related changes are more marked in individuals 
over the age of 50(22). In addition, our results are in keeping with previous work 
demonstrating that AIx, increases with advancing gestational from 28 weeks of gestation to 
term(23-25).  The pattern of AIx in this study, however, demonstrates a unique alteration in 
the expected pattern, i.e., the metformin group had an improvement in the AIx at AN3. This 
potential atypical trend was only present during the time of metformin treatment and 
reverted to the expected pattern at PN when metformin was stopped.  This further 
strengthens the proposed effects of metformin in this population group. 
Savidou et al(6) found that in patients with GDM, mean (SD) AIx (a measure of arterial wave 
reflection) was significantly higher compared to healthy controls, (13.1 ± 8.9% vs 0.7 ± 
11.4%; p<0.001), similarly, this study found a significant difference in the AIx values in 
  
women with GDM managed with metformin or diet modification in comparison to the 
control group . Our study found that at AN1, mean AIx was higher in the GDM-M group, 
4.90% (11.02), in comparison to controls. 
Savidou et al(6)  also found that in patients with GDM the mean (SD) PWV was marginally 
increased compared to healthy controls (6.0 ± 1.5 vs 5.4 ± 0.6 m/s; p =0.070). Similarly, in 
our study we found that the mean PWV is higher in women with GDM, with the mean value 
in the GDM-D group being 8.54 m/s (1.51) and in the GDM-M group being 8.97 m/s (1.71), 
in comparison to 8.28m/s in the healthy control group. However, the differences were not 
statistically significant, p=0.494 (Figure2). This re-affirms the findings from two previous 
studies(4, 5) which found that there was no significant difference in PWV between GDM and 
control groups. Additionally, we found that the mean difference between the stages of 
pregnancy was significant and observed that the pattern of PWV in the diet and healthy 
control group followed a pattern, grossly resembling a sine wave, similar to the findings of 
other studies of longitudinal changes of PWV during pregnancy(26, 27) .However, the 
metformin group did not demonstrate any such pattern. The PWV in the metformin group 
did not exhibit the characteristic reduction in the third trimester of pregnancy, remaining 
higher at AN3 and PN.  
The current study has several strengths. We have used a well-defined inclusion and 
exclusion criteria to limit the effect of any maternal condition on haemodynamic 
parameters. We have longitudinal follow-up to make sure that changes are directly related 
to the same group. In comparison, Savvidou et al(6) , however, had a GDM population that 
had a significantly higher blood pressure than the control subjects, and this may have 
influenced the results within the GDM group, as it is understood that PWV in known to 
increase with BP, and BP is a recognised determinant of aortic PWV(28-30). Equally, the 
control group in the study of Bulzico et al(5) had a higher prevalence of T2DM and 
cardiovascular disease in their first degree relatives(31), which may be associated with 
higher aortic stiffness(31).  Throughout our study, BP in both groups over all the four time 
points remained within the normal range, however Central mean (SD) BP was significantly 
higher in the GDM group in comparison to the healthy control, 67.02mmHG (13.25) vs 
61.25mmHG (9.57), p=0.02. Furthermore, Central diastolic BP and Central mean BP were 
significantly higher in the GDM metformin group compared to the healthy control group, 
  
p=0.01 and p=0.06, respectively. Therefore, it could be argued that the findings of an 
increased PWV in the GDM groups are a result of an increase in BP and possibly age. 
We cannot fully explain the cause of this interesting observation which may allude to 
Metformin having pleiotrophic actions yet unknown to us, therefore more research is 
necessary.  Even though we did not find that metformin had a significant effect on all 
maternal haemodynamic parameters in women with GDM, the mean difference (SD) 
between the GDM-M and GDM-D groups for aortic AIx at AN3 was statistically significant 
(p=0.033), the AIx in the GDM-M group changed more than in the GDM-D group,                     
-54.54%(22.85) vs -41.04 (31.48), respectively. This may be attributed to a possible 
beneficial effect of metformin on the vascular walls of arteries. Further work with larger 
studies are required to explore this pattern more closely.   
The study has certain limitations. The small number of participants (n=56), however, an 
attempt to overcome this was made with the longitudinal assessment of women on four 
separate occasions. Unfortunately, loss to follow-up is an understood weakness of a 
longitudinal study, and the authors found a higher loss to follow up in the postnatal period. 
This was attributed to the practical difficulties to a new mother in the puerperium. We 
employed the mixed effects model to account for the missing values. Ideally, a randomised 
controlled trial having defined arterial stiffness outcomes with a larger population and 
consistent methodological designs are required to further explore these findings. One could 
argue that the current observation may only be applicable to this population with a distinct 
ethnic mix. It was also noted that the GDM-M group had a greater mean (SD) fasting and 
2hr OGTT plasma glucose level in comparison to the GDM-D group, (4.53[0.62] vs. 
5.11[0.70]) and (8.07[0.92] vs. 8.54[1.22]), respectively. These findings demonstrate the 
potentially significant effect hyperglycaemia has on the vascular wall, even over a short 
duration in pregnancy, and highlighting the beneficial effects of metformin. This study did 
not evaluate women prior to 26 weeks of pregnancy, and therefore, women in the GDM 
group may have prior undiagnosed diabetes. However, as much as there is a case for 
glycaemic memory(32) influencing the haemodynamic measurements for the worse, there is 
a stronger case displaying the early and beneficial effects of metformin. There are numerous 
studies(33-36) recommending  that early intensive control of hyperglycaemia is able to 
reduce the risk of diabetic micro- and macro-vascular complications, therefore, the work 
  
done demonstrating the pleiotrophic effects of metformin are welcome. It is important to 
stress that the current study did not examine the risk of placental-mediated diseases. It is 
generally understood that arterial stiffness increases with age(30); however, our GDM-M 
group were younger than the GDM-D group and demonstrated an improvement in their AIx 
after metformin therapy.  
Even though there are no validation studies of the Arteriograph® in pregnancy, it has been 
extensively used in pregnancy research(21, 37, 38). The accuracy of SBP, PWV and AIx 
determination have been validated against invasive and non-invasive measurements(21, 
39), in non-pregnant populations. Furthermore, triplicate measurements  in a  previous 
repeatability study performed by the authors showed moderate-to-high correlation 
between observations on the same woman for all Arteriograph variables (estimates of intra-
class correlation ranged from 0.49 to 0.91)(40). 
  
CONCLUSION 
 
In conclusion, our study documented that that AIx and central systolic BP measures are 
adversely affected by GDM in comparison to controls during pregnancy. Metformin intake 
may influence changes in AIx over the course of pregnancy. The possible beneficial effects of 
metformin therapy seen at 32 to 34 weeks of gestation require further exploration in a 
future intervention trial.   
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Table 1: Baseline characteristics for all study participants at time of recruitment at AN1  
 
Continuous data are presented as mean (standard deviation) and categorical data are presented as 
count (% of total). 
 Control GDM diet GDM metformin 
n=60 n=23 n=33 
Age (years) 
  
29.71 (5.33) 33.13(4.72) 31.76(5.43) 
   
Height at booking (cm) 162.80 (7.09) 159.26(6.54) 163.33 (6.31) 
 
Baseline body weight at booking(kg) 66.1(9.6) 71.87(16.86) 82.48 (19.99) 
Body weight at recruitment (kg) 69.26 (16.79) 78.11(14.81) 88.00 (32.80) 
    
Body surface area (BSA)  at booking 
(m2)  
  
1.79(0.19) 1.80 (0.17) 1.93 (0.2) 
   
Body mass index (BMI) at booking  
(kg/m2) 
24.16(5.36) 27.96 (6.03) 32.13 (9.74) 
Body mass index (BMI) at recruitment  
(kg/m2) 
24.56(3.10) 30.76 (5.37) 32.80 (5.17) 
    
Gestational age at recruitment 
(weeks + days) 
28+2 (1.1) 28+3 (1.6) 27+2 (1.8) 
Gestational age at OGTT  
(weeks + days) 
 Not Available 28+3 (1.6) 27+2 (1.8) 
 Normal OGTT    
OGTT fasting ≥5.6mmol/litre  4.53(0.62) 5.11(0.70) 
OGTT 2hrs ≥7.8mmol/litre  8.07 (0.92) 8.54 (1.22) 
    
HBA1c  at AN2 (%)  Not available 5.26 (0.36) 5.57(0.43) 
HBA1c  at AN2 (mmol/mol) Not available 33.90 (4.04) 37.38(4.63) 
    
Parity P0 27 (45%) 8 (34.8%) 15 (45.4%) 
P1 26 (43.3%) 11(47.9) 9 (27.3%) 
P2 6   (10.0%) 2 (8.7%) 5 (15.3%) 
P3 0 1 (4.3%) 2 (6.0%) 
P4 1  (1.7%) 1 (4.3%) 0  
P5 0 0 2 (6.0%) 
 
Ethnicity Asian 2 (3.3%) 9 (39.1%) 7 (21.2%) 
Caucasian 53 (88.3%) 8 (34.8%) 15 (45.5%) 
African 4 (6.8%) 1 (4.4%) 8 (24.3%) 
Far East 0 3 (13%) 1 (3%) 
Middle East 1 (1.7%) 2 (8.7%) 2 (6%) 
    
 
  
 Weight, height, BSA and BMI are reported at time of recruitment to the study which is AN1 
 
  
Table 2: Mean (standard deviation) of maternal haemodynamic and arterial stiffness measurements in healthy pregnant (control) and 
gestational diabetes mellitus populations managed by diet or metformin at three antenatal and one post-partum gestational time-points  
  AN1 
26-28 weeks 
 AN2 
32-34 weeks 
 
 
AN3 
37-40 weeks 
 PN 
6-8 weeks 
 Group 
 
Stage Group: 
Stage 
interacti
on 
 Units  Contr
ol 
GDM
-D 
GDM
-M 
Contr
ol 
GDM
-D 
GDM
-M 
Contr
ol 
GDM
-D 
GDM
-M 
Contr
ol 
GDM
-D 
GDM
-M 
Glob
al p 
value 
Glob
al p 
value 
Global 
p 
value 
Heart 
rate 
Bpm 90.89 
(11.91
) 
90.14 
(11.7
0) 
92.19 
(9.45) 
93.57 
(11.20
) 
88.17 
(11.7
1) 
93.31 
(11.5
0) 
86.21 
(14.02
) 
79.94 
(11.5
6) 
85.28 
(15.7
2) 
76.15 
(9.35) 
73.79 
(10.2
1) 
71.87 
(11.7
3) 
0.190 <0.00
1 
 
NS 
Central 
Systoli
c BP 
mmH
g 
104.7
2 
(12.89
) 
107.0
4 
(11.3
5) 
114.8
8 
(21.3
8) 
 
111.4
9 
(13.41
) 
111.2
3 
(12.4
5) 
117.3
9 
(15.8
9) 
 
111.7
9 
(12.16
) 
108.4
0 
(11.5
3) 
116.2
1 
(15.4
1) 
 
110.3
3 
(10.84
) 
118.1
6 
(14.9
1) 
120.2
9 
(15.5
9) 
0.040 
 
<0.00
1 
 
0.001 
Central 
Diastol
ic BP 
mmH
g 
34.49 
(8.72) 
35.63 
(7.73) 
40.71 
(12.3
1) 
37.09 
(7.77) 
37.28 
(8.58) 
40.78 
(12.3
1) 
39.31 
(9.58) 
39.71 
(5.89) 
44.93 
(12.1
1) 
 
39.92 
(8.52) 
43.58 
(9.75) 
43.96 
(8.93) 
0.022 <0.00
1 
 
NS 
Central 
mean 
BP 
mmH
g 
57.90 
(9.58) 
59.53 
(8.31) 
65.43 
(14.8
2) 
37.09 
(7.77) 
62.69 
(9.32) 
66.32 
(12.5
4) 
 
63.47 
(9.69) 
62.61 
(6.72) 
68.69 
(13.9
9) 
 
63.38 
(8.75) 
68.44 
(11.1
3) 
69.40 
(10.6
7) 
0.011 <0.00
1 
 
NS 
Brachi
al AIx 
% - 
69.52 
(13.16
) 
-
61.19 
(15.9
2) 
-
55.61 
(21.8
0) 
- 
65.49 
(16.21
) 
-
46.26 
(29.9
9) 
-
56.63 
(19.3
5) 
- 
51.01 
(17.93
) 
-
41.04 
(31.4
8) 
-
54.54 
(22.8
5) 
- 
44.10 
(19.16
) 
-
24.21 
(27.5
9) 
-
24.25 
(30.7
8) 
 
0.002 
<0.00
1 
0.004 
Aortic 
AIx 
% 2.73 
(6.39) 
5.93 
(7.98) 
9.48 
(11.0
2) 
 
4.49 
(8.21) 
13.22 
(15.8
9) 
9.04 
(9.83) 
 
12.12 
(9.92) 
16.86 
(15.9
4) 
10.02 
(11.5
7) 
 
15.33 
(9.69) 
25.38 
(13.9
7) 
25.36 
(15.5
9) 
 
 
0.007 
 
0.000
2 
 
0.007 
  
PWV m/s 8.13 
(1.41) 
8.05 
(1.11) 
8.93 
(1.99) 
 
8.58 
(1.25) 
9.23 
(2.05) 
9.27 
(1.42) 
 
8.13 
(1.36) 
8.39 
(1.45) 
8.72 
(1.41) 
 
8.19 
(1.49) 
8.58 
(1.32) 
8.80 
(1.97) 
 
0.502 0.000
8 
 
NS 
 
 
Group: The p-value for the global main effect of group 
Stage: The p-value for the global main effect of gestational stage 
Group:Stage interaction: Statistical significance of the global two-way interaction of group and gestational stage.  
The global p-value indicates the p-value obtained from the F-statistics based on the type 3 analysis of variance. We considered the statistical 
significance as p<0.05. 
NS: Not Significant, i.e. the two-way interaction effect of group and gestational stage was not statistically significant (p>0.05) 
BP: blood pressure; AIx: augmentation index; PWV: pulse wave velocity; AN: ante-natal; PN: post-natal; GDM-D: gestational diabetes, diet 
controlled; GDM-M: gestational diabetes, metformin controlled;  
 
 
 
 
 
 
 
  
Supplementary Table 1: Mean (standard deviation) of maternal haemodynamic and arterial stiffness measurements in healthy pregnant 
(control) and gestational diabetes mellitus managed by diet modification (GDM-D) groups at three antenatal and one postpartum gestational 
time-points.  
  AN1 
26-28 weeks 
 AN2 
32-34 weeks 
 AN3 
37-40 weeks  
 PN 
6-8 weeks  
 Group: 
Stage 
interaction 
 Units Control GDM-
D 
P 
value 
Control GDM-
D 
P value Contro
l 
GDM-
D 
P 
value 
Control GDM-
D 
P 
value 
Global 
p value 
Heart 
rate 
Bpm 90.89 
(11.91) 
90.14 
(11.70) 
NA 93.57 
(11.20) 
88.17 
(11.71) 
NA 86.21 
(14.02) 
79.94 
(11.56) 
NA  76.15 
(9.35) 
73.79 
(10.21) 
NA NA 
Central 
Systolic 
BP 
mmHg 
104.72 
(12.89) 
107.04 
(11.35) 
1 
111.49 
(13.41) 
111.23 
(12.45) 
1 
111.79 
(12.16) 
108.40 
(11.53) 
0.43 
110.33 
(10.84) 
118.16 
(14.91) 
0.17 0.001 
Central 
Diastolic 
BP 
mmHg 
34.49 
(8.72) 
35.63 
(7.73) 
NA 
37.09 
(7.77) 
37.28 
(8.58) 
NA 
39.31 
(9.58) 
39.71 
(5.89) 
NA 
39.92 
(8.52) 
43.58 
(9.75) 
NA NA 
Central 
mean 
BP 
mmHg 
57.90 
(9.58) 
59.53 
(8.31) 
NA 
37.09 
(7.77) 
62.69 
(9.32) 
NA 
63.47 
(9.69) 
62.61 
(6.72) 
NA 
63.38 
(8.75) 
68.44 
(11.13) 
  NA NA 
Brachial  
AIx 
% -69.52 
(13.16) 
-61.19 
(15.92) 
0.06 -65.49 
(16.21) 
-46.26 
(29.99) 
<0.001 -51.01 
(17.93) 
-41.04 
(31.48) 
0.305 -44.10 
(19.16) 
-24.21 
(27.59) 
0.03 0.004 
Aortic  
AIx 
% 2.73 
(6.39) 
5.93 
(7.98) 
0.28 4.49 
(8.21) 
13.22 
(15.89) 
<0.001 12.12 
(9.92) 
16.86 
(15.94) 
0.429 15.33 
(9.69) 
25.38 
(13.97) 
0.04 0.007 
PWV m/s 8.13 
(1.41) 
8.05 
(1.11) 
NA 8.58 
(1.25) 
9.23 
(2.05) 
NA 8.13 
(1.36) 
8.39 
(1.45) 
NA 8.19 
(1.49) 
8.58 
(1.32) 
NA NA 
      
 
Data are mean (standard deviation). P value refers to group interaction, p<0.05 indicating significance. 
Group:Stage interaction: Statistical significance of the two-way interaction of group and gestational stage.  
  
The global p-value indicates the p-value obtained from the F-statistics based on the type 3 analysis of variance. We considered the statistical 
significance as p<0.05. 
NS: Not Significant, i.e. the two-way interaction effect of group and gestational stage was not statistically significant (p>0.05) 
NA: Not available, i.e. mean values between two groups at a given time point were not compared when the two-way interaction effect of 
group and gestational stage was not statistically significant (p>0.05). 
BP: blood pressure; AIx: augmentation index; PWV: pulse wave velocity; AN: antenatal; PN: postnatal; GDM-D: gestational diabetes diet 
controlled;  
 
  
Supplementary Table 2: Maternal haemodynamic and arterial stiffness measurements in healthy pregnant (control) and gestational diabetes 
mellitus managed with metformin (GDM-M) groups at three antenatal and one postpartum gestational time-points. 
 
   AN1 
26-28 weeks 
 AN2 
32-34 weeks 
 AN3 
37-40 weeks 
 PN 
6-8 weeks 
 Group:Stage 
interaction 
 Units  Control GDM-
M 
P value Control GDM-
M 
P 
value 
Control GDM-
M 
P 
value 
Normal GDM-
M 
P 
value 
Global p 
value 
Heart 
rate 
Bpm 90.89 
(11.91) 
92.19 
(9.45) 
NA 93.57 
(11.20) 
93.31 
(11.50) 
NA 86.21 
(14.02) 
85.28 
(15.72) 
NA 76.15 
(9.35) 
71.87 
(11.73) 
NA NA 
Central 
Systolic 
BP 
mmHg 
104.72 
(12.89) 
114.88 
(21.38) 
0.121 
111.49 
(13.41) 
117.39 
(15.89) 
1 
111.79 
(12.16) 
116.21 
(15.41) 
1 
110.33 
(10.84) 
120.29 
(15.59) 
0.228 0.0006 
Central 
Diastolic 
BP 
mmHg 
34.49 
(8.72) 
40.71 
(12.31) 
NA 
37.09 
(7.77) 
40.78 
(12.31) 
NA 
39.31 
(9.58) 
44.93 
(12.11) 
NA 
39.92 
(8.52) 
43.96 
(8.93) 
NA NA 
Central 
Mean 
BP 
mmHg 
57.90 
(9.58) 
65.43 
(14.82) 
NA 
37.09 
(7.77) 
66.32 
(12.54) 
NA 
63.47 
(9.69) 
68.69 
(13.99) 
NA 
63.38 
(8.75) 
69.40 
(10.67) 
NA NA 
Brachial 
AIx 
% -69.52 
(13.16) 
-55.61 
(21.80) 
0.020 -65.49 
(16.21) 
-56.63 
(19.35) 
0.158 -51.01 
(17.93) 
-54.54 
(22.85) 
1 -44.10 
(19.16) 
-24.25 
(30.78) 
0.023 0.04 
Aortic 
AIx 
% 2.73 
(6.39) 
9.48 
(11.02) 
0.034 4.49 
(8.21) 
9.04 
(9.83) 
0.22 12.12 
(9.92) 
10.02 
(11.57) 
1 15.33 
(9.69) 
25.36 
(15.59) 
0.036 0.007 
PWV m/s 8.13 
(1.41) 
8.93 
(1.99) 
NA 8.58 
(1.25) 
9.27 
(1.42) 
NA 8.13 
(1.36) 
8.72 
(1.41) 
NA 8.19 
(1.49) 
8.80 
(1.97) 
NA NA 
  
 
Data are mean (standard deviation). P value refers to group: gestational stage interaction for measurements at four time-points, p<0.05 
indicating significance. 
  
BP: blood pressure; AIx: augmentation index; PWV: pulse wave velocity; AN: ante-natal; PN: post-natal; GDM-D: gestational diabetes, diet 
controlled; GDM-M: gestational diabetes, metformin controlled;  
NA: Not available, i.e. mean values between two groups at a given time point were not compared when the two-way interaction effect of 
group and gestational stage was not statistically significant (p>0.05). 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1:  Measurements of Brachial AIx for participants in all three groups (points) at four time 
points (AN1, AN2, AN3, and PN) with the corresponding box plots showing the median and 
interquartile range.  
AN1: 26-28 weeks: Control (n=52), GDM-D (n=22) and GDM-M (n=33) 
AN2: 32-34 weeks: Control (n=51), GDM-D (n=18) and GDM-M (n=29) 
AN3: 37-40 weeks: Control (n=38), GDM-D (n=17) and GDM-M (n=18) 
PN: 6-8 weeks after delivery: Control (n=26), GDM-D (n=17) and GDM-M (n=15) 
 
  
  
 
 
Figure 2:  Measurements of Aortic AIx for participants in all three groups (points) at four time points 
(AN1, AN2, AN3, and PN) with the corresponding box plots showing the median and interquartile 
range. 
AN1: 26-28 weeks: Control (n=52), GDM-D (n=22) and GDM-M (n=33) 
AN2: 32-34 weeks: Control (n=51), GDM-D (n=18) and GDM-M (n=29) 
AN3: 37-40 weeks: Control (n=38), GDM-D (n=17) and GDM-M (n=18) 
PN: 6-8 weeks after delivery: Control (n=26), GDM-D (n=17) and GDM-M (n=15) 
 
 
 
 
 
 
  
  
 
 
 
Figure 2:  Measurements of PWV for participants in all three groups (points) at four time points 
(AN1, AN2, AN3, and PN) with the corresponding box plots showing the median and interquartile 
range. 
AN1: 26-28 weeks: Control (n=52), GDM-D (n=22) and GDM-M (n=33) 
AN2: 32-34 weeks: Control (n=51), GDM-D (n=18) and GDM-M (n=29) 
AN3: 37-40 weeks: Control (n=38), GDM-D (n=17) and GDM-M (n=18) 
PN: 6-8 weeks after delivery: Control (n=26), GDM-D (n=17) and GDM-M (n=15) 
 
 
 
 
 
 
